American Society of Clinical Oncology 2008 clinical practice guideline update: Use of chemotherapy and radiation therapy protectants Journal Article

  


Authors: Hensley, M. L.; Hagerty, K. L.; Kewalramani, T.; Green, D. M.; Meropol, N. J.; Wasserman, T. H.; Cohen, G. I.; Emami, B.; Gradishar, W. J.; Mitchell, R. B.; Thigpen, J. T.; Trotti, A.; von Hoff, D.; Schuchter, L. M.
Article Title: American Society of Clinical Oncology 2008 clinical practice guideline update: Use of chemotherapy and radiation therapy protectants
Abstract: Purpose To update a clinical practice guideline on the use of chemotherapy and radiation therapy protectants for patients with cancer. Methods An update committee reviewed literature published since the last guideline update in 2002. Results Thirty-nine reports met the inclusion criteria: palifermin and dexrazoxane, three reports ( two studies) each; amifostine, 33 reports ( 31 studies); and mesna, no published randomized trials identified since 2002. Recommendations Dexrazoxane is not recommended for routine use in breast cancer ( BC) in adjuvant setting, or metastatic setting with initial doxorubicin-based chemotherapy. Consider use with metastatic BC and other malignancies, for patients who have received more than 300 mg/m(2) doxorubicin who may benefit from continued doxorubicin-containing therapy. Cardiac monitoring should continue in patients receiving doxorubicin. Amifostine may be considered for prevention of cisplatin-associated nephrotoxicity, reduction of grade 3 to 4 neutropenia ( alternative strategies are reasonable), and to decrease acute and late xerostomia with fractionated radiation therapy alone for head and neck cancer. It is not recommended for protection against thrombocytopenia, prevention of platinum-associated neurotoxicity or ototoxicity or paclitaxel-associated neuropathy, prevention of radiation therapy associated mucositis in head and neck cancer, or prevention of esophagitis during concurrent chemoradiotherapy for non-small-cell lung cancer. Palifermin is recommended to decrease severe mucositis in autologous stem-cell transplantation (SCT) for hematologic malignancies with total-body irradiation (TBI) conditioning regimens, and considered for patients undergoing myeloablative allogeneic SCT with TBI-based conditioning regimens. Data are insufficient to recommend use in the non-SCT setting.
Keywords: oral mucositis; ovarian-cancer; neck-cancer; cell lung-cancer; phase-iii trial; randomized-trial; keratinocyte growth-factor; intravenous amifostine; intensive therapy; rectal toxicity
Journal Title: Journal of Clinical Oncology
Volume: 27
Issue: 1
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2009-01-01
Start Page: 127
End Page: 145
Language: English
ACCESSION: ISI:000262038500021
DOI: 10.1200/jco.2008.17.2627
PROVIDER: wos
PUBMED: 19018081
Notes: --- - Article - "Source: Wos"
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Tarun Kewalramani
    63 Kewalramani
  2. Martee L Hensley
    289 Hensley
Related MSK Work